Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
450
Trial Sponsor
Clinical Trial Start Date
October 7, 2019
0Primary Completion Date
July 22, 2020
0Study Completion Date
July 22, 2020
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Prevention0
Intervention Type
Biological0
Intervention Name
MVA-BN-WEV Dose 30
MVA-BN-WEV Dose 20
MVA-BN-WEV Dose 10
Interventional Trial Phase
Phase 10
Official Name
Phase 1 Vaccination Trial to Evaluate Safety, Tolerability and Immunogenicity of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects0
Last Updated
August 20, 2020
0Allocation Type
Non-Randomized0
Intervention Model
Parallel Assignment0
Masking Type
None (Open Label)0
Study summary
To assess safety and tolerability as well as immune responses to the MVA-BN-WEV vaccine in the 3 treatment groups receiving different doses.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
